Physician profile
Hailey E Hicks
NPI 1962973883
$2,690.31
in general payments reported to CMS, 2019-2025
28 companies · $501 in 2025
The $501 reported for 2025 was more than what 75% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.79 · 2022: $425 · 2023: $887 · 2024: $802 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,189.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $566.24 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $272.47 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Astrazeneca Pharmaceuticals LP | $229.00 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $191.62 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $165.66 | 2022-2024 | |
| Pfizer INC. | $147.49 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $106.10 | 2022-2025 | |
| Amgen INC. | $90.18 | 2023-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.41 | 2022-2025 | Jardiance |
| Abbott Laboratories | $85.20 | 2023-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $81.19 | 2023-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $79.72 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.94 | 2022-2023 | Xifaxan |
| Exact Sciences Corporation | $65.39 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $63.41 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $59.90 | 2022 | |
| Orexo US, INC. | $56.97 | 2021 | |
| Astellas Pharma US INC | $35.27 | 2023-2024 | Veozah |
| Idorsia Pharmaceuticals US INC | $34.58 | 2022-2023 | Quviviq |
| Antares Pharma, INC. | $32.36 | 2025 | Xyosted |
| Merck Sharp & Dohme LLC | $31.03 | 2022-2025 | Gardasil 9, Capvaxive |
| Currax Pharmaceuticals LLC | $30.54 | 2022-2023 | Nexlizet, Contrave, Nexletol |
| Madrigal Pharmaceuticals | $26.62 | 2025 | Rezdiffra |
| Sumitomo Pharma America, INC. | $20.03 | 2024 | Gemtesa |
| Sanofi Pasteur INC. | $17.52 | 2023 | |
| Noven Therapeutics, LLC | $16.82 | 2023 | Secuado |
| Glaxosmithkline, LLC. | $13.04 | 2022 | |
| Genentech USA, INC. | $7.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hailey Hicks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.